Small Cell Lung Cancer: From Foundations to Future Directions

Which of the following is the standard first-line treatment for limited-stage small cell lung cancer (LS-SCLC)?

• Surgery alone

• Etoposide-platinum chemotherapy with concurrent thoracic radiotherapy

• Pembrolizumab monotherapy

• Topotecan monotherapy

Answer explanation

The American College of Chest Physicians recommends early concurrent chemoradiotherapy with platinum-based chemotherapy (cisplatin or carboplatin plus etoposide) for LS-SCLC. Surgery is reserved for rare stage I cases, and immunotherapy is not standard in LS-SCLC.[1-3]

Which of the following statements regarding prophylactic cranial irradiation (PCI) in SCLC is most accurate?

• PCI is only indicated in extensive-stage SCLC with progressive disease

• PCI is recommended for LS-SCLC patients with no progression after initial therapy

• PCI is contraindicated in all SCLC patients

• PCI is only used in non-small cell lung cancer

Answer explanation

PCI reduces the risk of brain metastases and improves survival in patients with LS-SCLC who have responded to initial therapy, as recommended by the American College of Chest Physicians.[1-2]

Which of the following is the most common molecular alteration in SCLC?

• EGFR mutation

• ALK rearrangement

• TP53 and RB1 inactivation

• BRAF V600E mutation

Answer explanation

Nearly all SCLCs harbor inactivation of the tumor suppressor genes TP53 and RB1, which is a hallmark of the disease.[6]

Which of the following is the preferred imaging modality for routine surveillance of recurrence in patients with curatively treated stage I-III small cell lung cancer during the first two years posttreatment, according to the American College of Radiology?

• Chest X-ray
  

• PET/CT

• CT CAP, with IV contrast

• MRI chest with IV contrast

Answer explanation

The American College of Radiology recommends diagnostic chest CT, including the adrenal glands with IV contrast, as the preferred modality for surveillance during the first two years after curative treatment for stage I-III SCLC, due to its sensitivity for detecting recurrence and second primaries.[1]

According to the National Comprehensive Cancer Network, what is the recommended frequency of surveillance imaging (CT chest, abdomen, and pelvis) during the first year after curative therapy for stage I-III small cell lung cancer?

• Every 6 months

• Every 2 to 6 months

• Annually

• Only if symptoms develop

Answer explanation

The NCCN recommends CT imaging of the chest, abdomen, and pelvis every 2 to 3 months during the first year after curative therapy for stage I-III SCLC, reflecting the high risk of early relapse.[1]

What is the primary rationale for routine imaging surveillance in patients with small-cell lung cancer who have completed curative therapy?

• To monitor for chemotherapy toxicity

• To detect asymptomatic recurrence and second primary lung cancers

• To assess pulmonary function

• To evaluate cardiac function

Answer explanation

Routine surveillance is justified by the high risk of recurrence and the potential for early detection of salvageable disease and second primaries, as emphasized by the American College of Radiology.[1]

For patients with stage I-III small cell lung cancer who remain disease-free after three years posttreatment, what is the recommended interval for surveillance imaging according to NCCN guidelines?

• Every 2 to 3 months

• Every 3 to 4 months

• Biannually

• Annually

Answer explanation

After three years, the NCCN recommends annual surveillance imaging for patients who remain disease-free, reflecting the decreased but persistent risk of recurrence and second primaries.[1]

Which of the following statements best reflects the current consensus regarding maintenance therapy after first-line platinum-based chemotherapy in extensive-stage small cell lung cancer (ES-SCLC)?

• Maintenance therapy with immune checkpoint inhibitors significantly improves overall survival and is standard of care.

• Maintenance chemotherapy with agents such as etoposide or sunitinib is routinely recommended to prolong survival.

• Maintenance therapy with immune checkpoint inhibitors may improve progression-free survival, but has not demonstrated a significant overall survival benefit and is not standard of care.

• Maintenance therapy is recommended only for patients with limited-stage SCLC who achieve complete response.

Answer explanation

Multiple randomized trials and meta-analyses have shown that maintenance therapy, including chemotherapy and immune checkpoint inhibitors, does not confer a significant overall survival benefit in ES-SCLC, although some regimens may improve progression-free survival.[1-4] The American Society of Clinical Oncology guideline does not recommend routine maintenance therapy in this setting.[4]